ClinVar Miner

Submissions for variant NM_001009944.3(PKD1):c.9718G>A (p.Ala3240Thr)

gnomAD frequency: 0.00044  dbSNP: rs143312683
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000622983 SCV000742953 uncertain significance Inborn genetic diseases 2021-12-27 criteria provided, single submitter clinical testing The c.9718G>A (p.A3240T) alteration is located in exon 29 (coding exon 29) of the PKD1 gene. This alteration results from a G to A substitution at nucleotide position 9718, causing the alanine (A) at amino acid position 3240 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Athena Diagnostics Inc RCV001288342 SCV001475365 benign not specified 2020-01-30 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001292365 SCV001480769 uncertain significance Polycystic kidney disease no assertion criteria provided clinical testing The PKD1 p.Ala3240Thr variant was identified in 2 of 572 proband chromosomes (frequency: 0.003) from Czech and American individuals or families with ADPKD (Obeidova 2014, Rossetti 2012). The variant was also identified in dbSNP (ID: rs143312683) as “with uncertain significance allele”, ClinVar (classified as uncertain significance by Ambry Genetics), and ADPKD Mutation Database (classified as likely neutral). The variant was not identified in the LOVD 3.0 and PKD1-LOVD databases. The variant was identified in control databases in 119 of 252510 chromosomes at a frequency of 0.0005 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 3 of 21586 chromosomes (freq: 0.0001), Latino in 3 of 31912 chromosomes (freq: 0.00009), European Non-Finnish in 101 of 112472 chromosomes (freq: 0.0009), Ashkenazi Jewish in 1 of 9600 chromosomes (freq: 0.0001), European Finnish in 10 of 24550 chromosomes (freq: 0.0004), and South Asian in 1 of 29260 chromosomes (freq: 0.00003), while it was not observed in the Other or East Asian populations. In addition, we cannot be certain that data from control databases is specific to PKD1 and not from one of the six PKD1 pseudogenes. The p.Ala3240 residue is conserved in mammals but not in more distantly related organisms and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood the Thr variant impacts the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.